Skip to main content

Advertisement

SpringerLink
Log in

PET-positive bone lesion due to Langerhans cell histiocytosis after BEACOPP therapy for Hodgkin lymphoma: how anamnesis, histopathological accuracy, and molecular analysis could resolve a clinical dilemma

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Berres ML, Merad M, Allen CE (2015) Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X? Br J Haematol 169:3–13. https://doi.org/10.1111/bjh.13247

    Article  PubMed  Google Scholar 

  2. Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, Kuo FC, Ligon AH, Stevenson KE, Kehoe SM, Garraway LA, Hahn WC, Meyerson M, Fleming MD, Rollins BJ (2010) Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 116:1919–1923. https://doi.org/10.1182/blood-2010-04-279083

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Brown NA, Furtado LV, Betz BL, Kiel MJ, Weigelin HC, Lim MS, Elenitoba-Johnson KS (2014) High prevalence of somatic MAP2K1 mutations in BRAF V600E–negative Langerhans cell histiocytosis. Blood 124:1655–1658. https://doi.org/10.1182/blood-2014-05-577361

    Article  CAS  PubMed  Google Scholar 

  4. Pina-Oviedo S, Medeiros LJ, Li S, Khoury JD, Patel KP, Alayed K, Cason RC, Bowman CJ, Yin CC (2017) Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations. Mod Pathol 30:734–744. https://doi.org/10.1038/modpathol.2016.235

    Article  CAS  PubMed  Google Scholar 

  5. Christie LJ, Evans AT, Bray SE, Smith ME, Kernohan NM, Levison DA, Goodlad JR (2006) Lesions resembling Langerhans cell histiocytosis in association with other lymphoproliferative disorders: a reactive or neoplastic phenomenon? Hum Pathol 37:32–39. https://doi.org/10.1016/j.humpath.2005.08.024

    Article  CAS  PubMed  Google Scholar 

  6. Mesguich C, Cazeau AL, Bouabdallah K, Soubeyran P, Guyot M, Milpied N, Bordenave L, Hindié E (2016) Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation. Br J Haematol 175:652–660. https://doi.org/10.1111/bjh.14292

    Article  PubMed  Google Scholar 

  7. Naumann R, Beuthien-Baumann B, Fischer R, Kittner T, Bredow J, Kropp J, Ockert D, Ehninger G (2002) Simultaneous occurrence of Hodgkin’s lymphoma and eosinophilic granuloma: a potential pitfall in positron emission tomography imaging. Clin Lymphoma Myeloma Leuk 3:121–124. https://doi.org/10.3816/CLM.2002.n.019

    Article  Google Scholar 

  8. Shin MS, Buchalter SE, Ho KJ (1994) Langerhans cell histiocytosis associated with Hodgkin’s disease: a case report. J Natl Med Assoc 86:65–69

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Egeler RM, Neglia JP, Arico M, Favara BE, Heitger A, Nesbit ME, Nicholson HS (1998) The relation of Langerhans cell histiocytosis to acute leukaemia, lymphomas, and other solid tumors. The LCH-Malignancy Study Group of the Histiocyte Society Hematol Oncol Clin North Am 12:369–378. https://doi.org/10.1016/S0889-8588(05)70516-5

    Article  CAS  Google Scholar 

  10. Natoli A, Lüpertz R, Merz C, Müller WW, Köhler R, Krammer PH, Li-Weber M (2013) Targeting the IL-4/IL-13 signaling pathway sensitizes Hodgkin lymphoma cells to chemotherapeutic drugs. Int J Cancer 133:1945–1954. https://doi.org/10.1002/ijc.28189

    Article  CAS  PubMed  Google Scholar 

  11. Loghavi S, Khoury JD (2017) Langerhans cell histiocytosis in a patient with hairy cell leukemia: a tale of divergence. Blood 129:1563. https://doi.org/10.1182/blood-2016-11-749374

    Article  PubMed  Google Scholar 

  12. Ryland GL, Jones K, McBean M, Khot A, Seymour JF, Blombery P (2017) Comprehensive genomic characterization dissects the complex biology of a case of synchronous Burkitt lymphoma and myeloid malignancy with shared hematopoietic ancestry. Leuk Lymphoma 9:1–4. https://doi.org/10.1080/10428194.2017.1361029

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Pathology, University Hospital Basel, Basel, Switzerland

    Simon Haefliger, Michel Bihl & Alexandar Tzankov

  2. Department of Oncology, University Hospital Basel, Basel, Switzerland

    Fatime Krasniqi

  3. Division of Histopathology and Autopsy, Institute of Pathology, University Hospital Basel, Schonbeinstrasse 40, CH, 4031, Basel, Switzerland

    Alexandar Tzankov

Authors
  1. Simon Haefliger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michel Bihl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fatime Krasniqi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alexandar Tzankov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexandar Tzankov.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Statement of informed consent

The patient has given a written consent to publish her case.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Haefliger, S., Bihl, M., Krasniqi, F. et al. PET-positive bone lesion due to Langerhans cell histiocytosis after BEACOPP therapy for Hodgkin lymphoma: how anamnesis, histopathological accuracy, and molecular analysis could resolve a clinical dilemma. Ann Hematol 97, 355–357 (2018). https://doi.org/10.1007/s00277-017-3145-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-017-3145-0

Search

Navigation